1Antithrombotic Trialists′ Collaboration.Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71-86.
2Steinhubl SR,Berger PB,Mann JT,et al.Clopidogrel for the reduction of events during observation.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial[J].JAMA,2002,288(19):2411-2420.
3Neumann FJ,Blasini R,Schmitt C,et al.Effect of glycoprotein Ⅱb/Ⅲa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction[J].Circulation,1998,98(24):2695-2
4Brown BG,Zhao XQ,Sacco DE,et al.Lipid lowering and plaque regression.New insights into prevention of plaque disruption and clinical events in coronary disease[J].Circulation,1993,87(6):1781.
6Col NF,Mclaughlin TJ,Soumerai SB,et al.The impact of clinical trials on the use of medications for acute myocardial infarction[J].Arch Intern Med,1996,156(1):54-60.
7Chen J,Radford MJ,Wang Y,et al.Do ""America's Best Hospitals"" perform better for acute myocardial infarctions[J].N Engl J Med,1999,340(4):286-292.
8CAPRIE Steering Committee.A randomized trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE)[J].Lancet,1996,348:1329-1339.
9The CURE Trial Investigators.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation[J].N Engl J Med,2001,345(7):494-502.
10The EPIC Investigators.Use of monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956-961.
